Bionik Laboratories Corp.
Healthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.3M | $1.2M | $2.2M | — | $987,431 |
| Operating income | −$4.8M | −$10.0M | −$13.3M | −$25.1M | — | — |
| Net income | −$4.9M | −$10.4M | −$13.6M | −$25.0M | $10.6M | $14.6M |
| Total assets | $3.4M | $4.7M | $8.8M | $18.5M | $30.7M | $28.6M |
| Total liabilities | $5.0M | $1.7M | $5.5M | $5.2M | — | — |
| Equity | −$1.6M | $2.9M | $3.3M | $13.3M | $27.4M | $20.5M |
| EPS (diluted) | $-0.72 | $-1.78 | $-2.66 | — | — | — |
| Shares out. | 12.5M | 6.8M | 5.6M | 5.0M | 3.7M | 247.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −267.3%
- Net margin
- −274.0%
- Return on equity
- 301.5%
- Return on assets
- −147.1%
- Return on capital (ROCE)
- −458.2%
- Liabilities / assets
- 148.8%
- Debt / equity
- —
- Book value / share
- $-0.13
- Revenue growth (YoY)
- 41.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -106.37distress
- Accruals / assets
- −46.4%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2015
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2015
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2014
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2012
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2012
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Gaston-Dreyfus RemiDirector | Jun 13, 2023 | Conversion | 3.1M | $0.60 |
| Auberton-Herve Andre-JacquesDirector | Jun 13, 2023 | Conversion | 186,111 | $0.60 |
| Matine CharlesDirector | Jun 9, 2023 | Buy | 180,555 | $0.60 |
| Gaston-Dreyfus RemiDirector | Jun 9, 2023 | Buy | 180,555 | $0.60 |
| Auberton-Herve Andre-JacquesDirector | Jun 9, 2023 | Buy | 650,000 | $0.60 |
| Auberton-Herve Andre-JacquesDirector | Jul 15, 2021 | Option exercise | 51,878 | $3.60 |
| Gaston-Dreyfus RemiDirector | Mar 31, 2022 | Conversion | 77,887 | $9.50 |
| Gaston-Dreyfus RemiDirector | Jul 15, 2021 | Option exercise | 115,759 | — |
| Gaston-Dreyfus RemiDirector | Mar 29, 2021 | Grant | 61,256 | — |
| Gaston-Dreyfus RemiDirector | Mar 26, 2021 | Buy | 135,560 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer changeJun 27, 2023
- Entered a material agreement · New financial obligation · Unregistered equity sale · Other material eventJun 16, 2023
- Unregistered equity saleJun 16, 2023
- Regulation FD disclosureJun 15, 2023
- Regulation FD disclosureMay 23, 2023
- Regulation FD disclosureMay 4, 2023
- Entered a material agreement · New financial obligation · Unregistered equity saleApr 26, 2023
- Entered a material agreement · New financial obligation · Unregistered equity saleFeb 23, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GJun 30, 2023
- 8-KFORM 8-KJun 27, 2023
- 10-KJun 21, 2023
- S-8 POSJun 21, 2023
- 4OWNERSHIP DOCUMENTJun 21, 2023
- 4OWNERSHIP DOCUMENTJun 21, 2023
- 4OWNERSHIP DOCUMENTJun 21, 2023
- 4OWNERSHIP DOCUMENTJun 21, 2023
- 4OWNERSHIP DOCUMENTJun 21, 2023
- 8-KFORM 8-KJun 16, 2023
- 8-KFORM 8-KJun 16, 2023
- 8-KFORM 8-KJun 15, 2023
- SDFORM SDMay 31, 2023
- 8-KFORM 8-KMay 23, 2023
- 8-KFORM 8-KMay 4, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.